NEW YORK, June 23 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Brian Levy, OD, MSc as its Chief Operating Officer.
"Dr. Levy's depth and breathe of experience in clinical operations, drug and device development and medical affairs make him an excellent addition to Danube's senior management team. I look forward to his working with us in successfully developing our drug candidates and expanding our pipeline," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.
Prior to joining Danube, since 2004, Dr. Levy served as Corporate Vice President and Chief Medical Officer of Bausch & Lomb worldwide. He was responsible for clinical development and research, global product safety and medical affairs. In this role Dr. Levy drove the development and subsequent approval of multiple ophthalmic pharmaceutical products and ophthalmic devices globally, including the only approved intra-ocular sustained release steroid drug delivery system. Dr. Levy joined Bausch & Lomb in 1994 as Director, Medical Clinical Affairs. Prior to joining Bausch & Lomb, from 1989 to 1994, Dr. Levy served as Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco. Before that he studied epidemiology and biostatistics in vision research through the National Institutes of Health and then proceeded into private clinical practice for 10 years. During this period Dr. Levy was a clinical investigator for numerous products in development and an advisor and consultant to the ophthalmic industry.
Dr. Levy currently holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester's School of Medicine. He received a Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in comparative anatomy and physiology of the eye at the University of Waterloo in Canada, where he received a Master of Science degree. Dr. Levy has published widely in peer-reviewed journals and has presented nationally and internationally at scientific and educational symposia of Ophthalmology.
About Danube Pharmaceuticals, Inc.
Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit http://www.danubepharma.com.
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statements. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.
|SOURCE Danube Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved